Pharmaron Beijing Co., Ltd. (SHE:300759)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Laboratory Services (Excl. Macromolecule and Cell and Gene Therapy Services)	8.16B	7.05B	6.66B	-	4.57B
CMC (Small Molecule CDMO) Service	3.48B	2.99B	2.71B	2.41B	1.75B
Clinical Development Services	1.96B	1.83B	1.74B	1.39B	956.36M
Biologics and CGT Services	474.69M	407.52M	424.94M	351.03M	150.97M
Others	21.90M	6.40M	4.61M	26.19M	24.48M
Laboratory Services	-	-	-	6.09B	-
Total	14.10B	12.28B	11.54B	10.27B	7.44B

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
North America	8.71B	7.85B	7.40B	6.64B	4.78B
Europe	2.89B	2.27B	1.84B	1.48B	1.16B
Others	50.69M	39.51M	48.87M	25.01M	33.96M
Mainland China	2.14B	1.85B	1.97B	1.88B	1.27B
Asia (Excluding Chinese Mainland)	298.44M	264.27M	269.04M	233.48M	192.87M
Total	14.10B	12.28B	11.54B	10.27B	7.44B

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 31, 2026

Data Sources Report a data error